^
Association details:
| Biomarker: | ERCC1 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Zejula (niraparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer
Excerpt:
...we then focused on validating these results by using two clinically relevant PARP1/2 inhibitors, namely olaparib (AZD-2281, Astra Zeneca, London, UK) and olaparib (MK-4827, TesaroBio, Waltham, MA, USA). Both compounds displayed significant selectivity towards the ERCC1-deficient clones, which were 10–100 times more sensitive to the PARP1/2 inhibitors than their ERCC1-proficient counterpart...
